Investor Presentaiton
CSL Seqirus
Operational Highlights.
•
Seasonal influenza
products
FLUCELVAX® 6-month+ age
extension approved in UK,
Australia and New Zealand
FLUADⓇ
-
50-year+ age extension
approved in the EU.
Received preferential
recommendation in Canada
for the 65+ population.
•
•
Product Innovation
Phase III clinical study
commenced for aQIVC
Regulatory approval for world
first sa-mRNA COVID vaccine
Japanese approval for ARCT-
154
R&D development program
beyond influenza
Phase 1 trial for sa-mRNA for
seasonal and pandemic influenza
.
Pandemic influenza
UK Advance Purchase Agreement
awarded solely to CSL Seqirus
Selected by BARDA for delivery of
H5N8 A/Astrakhan antigen to the
U.S. government for preparedness
against potential avian flu outbreak
in humans
8
Driven by Our Promise
CSLView entire presentation